Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.51 |
| ▸ | MET | P08581 | 4/20 | 0.51 |
| ▸ | MERTK | Q12866 | 4/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | CDC25C | P30307 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29812561 | 0.99 | AXL (0.50) | AXLMETMERTKTYRO3IKBKB | |
| SCHEMBL15334264 | 0.87 | AXL (0.49) | AXLMETMERTKTYRO3SLC6A4 | |
| SCHEMBL23882496 | 0.83 | AXL (0.48) | AXLMETMERTKTYRO3SLC6A4 | |
| SCHEMBL15328107 | 0.81 | MET (0.50) | AXLMETIKBKBCHUKSLC6A4 | |
| SCHEMBL15334268 | 0.81 | KDM4E (0.49) | AXLMET | |
| SCHEMBL30672130 | 0.81 | MERTK (0.45) | AXLMETMERTKTYRO3 | |
| SCHEMBL29812460 | 0.80 | IKBKB (0.42) | AXLMETIKBKBCHUKSLC6A4 | |
| SCHEMBL29626199 | 0.78 | MKNK1 (0.48) | MERTK | |
| SCHEMBL29812235 | 0.78 | AXL (0.42) | AXLMETMERTKTYRO3IKBKB | |
| SCHEMBL29812513 | 0.78 | IKBKB (0.39) | AXLMETMERTKIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284043-A | Tricyclic compound and medical application thereof | 中国科学院上海药物研究所 | 2023-06-23 | — | — | CN | disclosed |
| CN-114787144-A | Pyridone compounds and methods for modulating protein kinases | 埃克塞里艾克西斯公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| WO-2020042618-A1 | MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF | 北京越之康泰生物医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | CSF1R, CSF3R, FLT3 | AXL 102/4885MET 246/4885MERTK 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.